- Home
- APVO vs PRPH Comparison
APVO vs PRPH Comparison
Compare APVO & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- PRPH
- Stock Information
- Founded
- APVO 2016
- PRPH 1989
- Country
- APVO United States
- PRPH United States
- Employees
- APVO N/A
- PRPH N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- PRPH Health Care
- Exchange
- APVO Nasdaq
- PRPH Nasdaq
- Market Cap
- APVO 21.7M
- PRPH 21.9M
- IPO Year
- APVO N/A
- PRPH 1997
- Fundamental
- Price
- APVO $1.09
- PRPH $0.19
- Analyst Decision
- APVO
- PRPH
- Analyst Count
- APVO 0
- PRPH 0
- Target Price
- APVO N/A
- PRPH N/A
- AVG Volume (30 Days)
- APVO 757.7K
- PRPH 1.2M
- Earning Date
- APVO 11-06-2025
- PRPH 11-19-2025
- Dividend Yield
- APVO N/A
- PRPH N/A
- EPS Growth
- APVO N/A
- PRPH N/A
- EPS
- APVO N/A
- PRPH N/A
- Revenue
- APVO N/A
- PRPH $5,588,000.00
- Revenue This Year
- APVO N/A
- PRPH $221.82
- Revenue Next Year
- APVO N/A
- PRPH N/A
- P/E Ratio
- APVO N/A
- PRPH N/A
- Revenue Growth
- APVO N/A
- PRPH N/A
- 52 Week Low
- APVO $1.07
- PRPH $0.18
- 52 Week High
- APVO $298.00
- PRPH $0.93
- Technical
- Relative Strength Index (RSI)
- APVO 27.92
- PRPH 24.66
- Support Level
- APVO $1.39
- PRPH $0.24
- Resistance Level
- APVO $1.54
- PRPH $0.29
- Average True Range (ATR)
- APVO 0.09
- PRPH 0.04
- MACD
- APVO -0.03
- PRPH -0.01
- Stochastic Oscillator
- APVO 3.06
- PRPH 2.53
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.